5 Signs Your Lab Has Outgrown Spreadsheet-Based Sample Tracking (and What to Do Next)
Spreadsheets have supported life sciences teams for decades. They’re familiar, flexible, and quick to set up. But as labs scale, especially in regulated environments like cell therapy, biobanking, and advanced biologics – what once worked can quietly become a source of risk. Over the years, our team at Pragmatrix has had the opportunity to work alongside CDMOs, CMOs, and biotech organizations navigating this exact transition. A consistent pattern emerges: spreadsheets don’t usually “fail” overnight. They simply stop keeping pace with operational and regulatory realities. Here are five signs your lab may have outgrown spreadsheet-based sample tracking and key considerations for …
Scaling CAR-T Operations: The 7 Handoffs That Require End-to-End Traceability
Personalized cell therapies don’t fail at a single point. They strain at the transitions. Across the CAR-T journey, patient material moves through multiple teams, locations, and systems – each governed by strict FDA regulations, GMP requirements, and SOPs. What has been observed over years of supporting cell therapy organizations is that handoffs, not core science, are where complexity quietly accumulates. Each transition introduces a moment where visibility can narrow, documentation can fragment, and coordination becomes harder than expected. Understanding these handoffs and what they require to remain compliant is increasingly important for CMOs, CDMOs, and biobanks scaling advanced therapy programs. …
Apheresis Scheduling in Cell Therapy: How It Works and Where Alignment Breaks Down
Apheresis scheduling is one of the most time-sensitive steps in the cell and gene therapy (CGT) lifecycle. On paper, the process appears linear: schedule the patient, collect cells, move to manufacturing. In real-world GMP environments, apheresis scheduling is rarely that simple. It sits at the intersection of patient readiness, collection site capacity, manufacturing availability, and regulated logistics. When these elements are not aligned, small scheduling changes can cascade across the supply chain – often without immediate visibility. Across CMOs, CDMOs, and therapy developers, a consistent pattern emerges: scheduling itself is not the problem – disconnected processes are. This article explains …
Autologous vs. Allogeneic Cell Therapies: Supply Chain Differences That Impact Scale and Compliance
Autologous and allogeneic cell therapies are often compared from a scientific or clinical perspective. For organizations responsible for manufacturing and delivery, however, the most meaningful differences appear in the supply chain. These therapies follow fundamentally different operational models. Treating them as minor variations of the same workflow is one of the most common reasons cell and gene therapy (CGT) supply chains struggle to scale. Across CMOs, CDMOs, and therapy developers, a consistent pattern has emerged: when supply chain design does not reflect the underlying therapy model, compliance risk increases, timelines extend, and teams rely on manual workarounds that were never …
5 Questions Every Cell Therapy Organization Should Ask Before Their Next FDA Audit
Preparing for an FDA audit in cell therapy isn’t just about documentation, it’s about readiness across people, processes, and technology. For patients whose treatment depends on precise, time-sensitive coordination, every operational detail matters. A single delay in scheduling, a missing timestamp, or an outdated SOP can extend a patient’s wait for a therapy they urgently need. In recent years, our team at Pragmatrix has observed one pattern across CMOs, CDMOs, and therapy developers: successful audits don’t happen in the audit room. They happen in the months leading up to it – inside workflows, touchpoints, and systems that either support teams …
Cell and Gene Therapy Trends for 2026: Navigating the Evolution of Advanced Therapeutics
By the end of 2026, the way we manufacture cell and gene therapies will look fundamentally different than it does today. Not because of scientific breakthroughs alone, but because operational realities are forcing a transformation that’s long overdue. The cell and gene therapy (CGT) landscape stands at a pivotal moment. With over 3,700 therapies in clinical and preclinical development and 76 products already launched globally, 2026 promises to be a defining year where innovation meets operational reality. For patient-centric organizations, CMOs, and CDMOs, understanding these emerging trends is not just about staying current, it’s about positioning your operations for sustainable …
Supply Chain Integration with PragLife: Orchestrating Seamless Connectivity Across the Cell & Gene Therapy Ecosystem
In cell and gene therapy manufacturing, the difference between a life-saving treatment reaching a patient on time and a critical delay often comes down to one factor: supply chain integration. The complexity is staggering. A single CAR-T therapy journey involves coordinating patient enrollment, apheresis scheduling, cryopreservation, transportation across multiple time zones, GMP manufacturing, quality control, final product delivery, and patient infusion, all while maintaining perfect Chain of Identity (COI) and Chain of Custody (COC) at every touchpoint. Manual coordination across these stakeholders is not just inefficient. It’s a patient safety risk. The Integration Imperative in Personalized Therapies Cell and gene …
